Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-09-08
1999-09-14
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514457, 514152, 514858, 514859, 514860, 514861, 514863, 514864, A61K 3135, A61K 3165
Patent
active
059523735
DESCRIPTION:
BRIEF SUMMARY
DESCRIPTION
Agents against hyperreactive and hypoactive, deficiency states of the skin and manifest dermatitis.
The present invention particularly relates to active compounds and formulations, in particular for topical use, which are used for prophylaxis and treatment of hyperreactive skin predisposed to dermatitis, and of deficient hypoactive skin and for prophylaxis and treatment of the manifest dermatoses mentioned under I. to XIII., such as, for example, atopic dermatitis, neurodermatitis, atopic eczema and seborrhoeic dermatitis, photoinduced dermatoses (for example Mallorca acne and in particular polymorphic photodermatosis and photodermatitis), rosacea, prurigo forms, pruritus, psoriasis forms, ichthyosis, decubitus, ulcus cruris and microbial and viral infections, such as, for example, herpes simplex, h.zoster or h.labialis.
The skin states according to the invention are explained below in more detail.
Various pathological mechanisms which characterize the clinical picture of hypoactive skin or hyperreactive skin and the dermatoses mentioned under I. to XIII., such as, for example, forms of acne, atopic dermatitis, prurigo forms, psoriasis, photodermatoses, decubitus, ulcus cruris and ichthyosis, are described in the literature. However, the causal pathological mechanisms and the chronology thereof are not sufficiently known for any of the dermatoses mentioned. The treatment methods and active compounds administered which are known to date lead in the most favourable case to a brief improvement in the symptoms. UV treatment and/or chemotherapy (psoralen, PUVA, cyclosporin A, corticosteroids, acyclovir and the like), for example, are used for treatment, with the known adverse side effects on repeated administration.
The object of the invention is to improve this unsatisfactory prior art and to provide cosmetic, dermatological and/or pharmaceutical active compounds and formulations which are used for prophylaxis and treatment of deficient, hypoactive skin or for prophylaxis and treatment of hyperreactive skin with a propensity to dermatitis, and for prophylaxis and treatment of the manifest dermatoses mentioned under sections I. to XIII. below, without inducing the side effects of known agents, even during long-term use.
These objects are achieved according to the invention.
The invention relates to the use of or compounds chosen from the group consisting of flavonoids, in combination with a compound or several compounds chosen from the group consisting of cinnamic acid derivatives, and if appropriate additionally in each case a compound or several compounds from one of the groups or several of the groups derivatives thereof (mimics) or skin predisposed to dermatitis or deficient, hypoactive skin or dermatoses.
Active compound combinations b), their use and formulations which comprise these are preferred.
The invention also relates to cosmetic and dermatological formulations, in particular topical formulations and pharmaceutical preparations, having a content of the abovementioned active compounds for treatment and prophylactic treatment of the abovementioned states of the skin or diseases.
The invention also relates to cosmetic and dermatological, in particular topical formulations and pharmaceutical preparations having a content of the abovementioned active compounds according to the invention.
The manifest dermatoses or skin diseases (dermatitis) according to the invention and the most important forms and names thereof are, in particular: pustulous, nodose, i.e. nodular, nodulocystic acne) acne forms (for example chlorine acne) Feyrter, vulvovaginitis herpetica, keratoconjunctivitis herpetica, herpes simplex recidivans, herpes genitalis recidivans, herpes glutaelis recidivans, dermatitis herpetiformis) zona) Streptococci, Staphylococci) follicular pyodermas (cocci), furuncles, carbuncles, folliculitis, for example f. barbae subtilis, E. coli, S. aureus) are PPD, PPE and a large number of other names such as are mentioned in the literature (for example A. Voelckel et al., Zentralblatt Haut- und Ge
REFERENCES:
patent: 4297348 (1981-10-01), Frazier
patent: 5719129 (1998-02-01), Andary et al.
The Merck Index, 10.sup.th Ed., Windholz et al., p. 1315, abstract No. 9021. (1983).
Lanzendorfer Ghita
Stab Franz
Untiedt Sven
Beiersdorf AG
Weddington Kevin E.
LandOfFree
Agents acting against hyperreactive and hypoactive, deficient sk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents acting against hyperreactive and hypoactive, deficient sk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents acting against hyperreactive and hypoactive, deficient sk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510243